Document is current

Article History

Received: 28 October 2024

Accepted: 19 December 2024

First Online: 31 December 2024

Declarations

:

: Not applicable.

: The use of patients’ personal and clinical data is authorized by a European Directive that states that pharmacovigilance systems should use all appropriate measures to obtain accurate, verifiable information for the scientific evaluation of suspected adverse reaction reports, including reidentification of records identifying ADRs []. MNO, LMS, ALR, AB, EH and EP are members of the regional pharmacovigilance centres, an integral part of the French national pharmacovigilance system under the aegis of the French Medicine Agency ANSM.Written informed consent was obtained from the patient for publication of this case report.

: The authors declare no competing interests.